Advanced Search

Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2004 June;56(2) > Minerva Urologica e Nefrologica 2004 June;56(2):147-63



A Journal on Nephrology and Urology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536

Frequency: Bi-Monthly

ISSN 0393-2249

Online ISSN 1827-1758


Minerva Urologica e Nefrologica 2004 June;56(2):147-63


Medical therapy of prostate carcinoma

Carmignani G. 1, Oneto F. 2

1 Urology Unit Department of Surgical Anesthesiological Sciences and Transplantations (DiSCAT) University of Genoa, Genoa, Italy
2 Urology S. Martino Hospital, Genoa, Italy

Medical treat­ment of pros­tat­ic can­cer is one of the ­most com­plex and chal­leng­ing is­sues in on­co­log­ic urol­o­gy, and prob­ably of on­col­o­gy it­self. In ­fact, in ­spite of the ­well ­known sen­si­tiv­ity of the dis­ease to hor­mo­nal ma­nip­u­la­tions, it is ­still sub­stan­tial­ly un­clear wheth­er hor­mo­nal ther­a­py ­achieves sur­vi­val im­prove­ment. Furthermore, ­many pros­tate can­cers be­come hor­mone re­frac­to­ry with­in 18 to 36 ­months ­from the on­set of ther­a­py, and un­til now, no fur­ther treat­ment has ­been ­able to im­prove ­their prog­no­sis, in ­spite of the of­ten prom­is­ing ear­ly re­sults. Medical treat­ment is now be­ing ­used as an ad­junct to rad­i­cal sur­gery and to ra­dio­ther­a­py, in ­both the ad­ju­vant and the neo­ad­ju­vant set­ting, and ­this rais­es fur­ther con­tro­ver­sies. This ­paper is an at­tempt to ­give to the read­ers the ­state of art of med­i­cal ther­a­py, ­even with­in the lim­its of a con­cise re­view. The au­thors are ­aware of ­these lim­its but ­hope ­that ­this ­paper can be use­ful to the read­er.

language: English, Italian


top of page